Patent win for PDS Biotech (NASDAQ: PDSB) on lead PDS0101 asset

Rhea-AI Filing Summary

PDS Biotechnology Corporation reported that the U.S. Patent Office has issued a Notice of Allowance for a patent covering its lead asset, PDS0101. A Notice of Allowance means the patent application has been approved and a patent is expected to be granted once final formalities and fees are completed.

The company highlighted this development in a press release attached to the report. Strengthening patent protection around a lead drug candidate can help secure future commercial exclusivity if the product is successfully developed and approved, although this filing does not provide clinical or financial details.

Insights

Biotech IP and pipeline analyst

PDS Biotech secures patent allowance for lead cancer asset PDS0101.

PDS Biotechnology states that the U.S. Patent Office has issued a Notice of Allowance for a patent related to its lead asset PDS0101. In drug development, this step usually precedes formal patent issuance, which can help protect the commercial position of a key program if it reaches the market.

The filing does not describe the patent’s claims, term, or the specific indications covered, so the exact scope of protection is unclear from this excerpt. Still, tying the allowance to the company’s lead asset suggests management views this intellectual property as strategically important.

The main near-term implication is an incremental strengthening of the company’s intellectual property portfolio around PDS0101. Future press releases, clinical updates, or full patent texts would be needed to assess how this interacts with trial progress, competitive products, and eventual market strategy.

false0001472091NASDAQ00014720912026-01-222026-01-22

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 22, 2026

PDS BIOTECHNOLOGY CORPORATION

(Exact Name of Registrant as Specified in Charter)

Delaware	001-37568	26-4231384
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

303A College Road East, Princeton, NJ 08540

(Address of Principal Executive Offices, and Zip Code)

(800) 208-3343

Registrant’s Telephone Number, Including Area Code

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.00033 per share	PDSB	The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Yes ☐ No ☐

Item 8.01 Other Events.

On January 22, 2026, PDS Biotechnology Corporation (the “Company”) issued a press release announcing that U.S. Patent Office has issued a Notice of Allowance for the Company’s lead asset, PDS0101.

 A copy of the press release is filed herewith as Exhibit 99.1 and incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description
99.1		Press Release Dated January 22, 2026.
104		Cover Page Interactive Data File (embedded within the Inline XBRL Document).

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		PDS BIOTECHNOLOGY CORPORATION
	Date:  January 22, 2026	By:	/s/ Frank Bedu-Addo, Ph.D.
		Name: Frank Bedu-Addo, Ph.D.
		Title: President and Chief Executive Officer

FAQ

What did PDSB announce in this Form 8-K filing?

PDS Biotechnology Corporation announced that the U.S. Patent Office has issued a Notice of Allowance for a patent related to its lead asset, PDS0101.

What is the significance of the Notice of Allowance for PDSBs PDS0101?

A Notice of Allowance indicates that the U.S. Patent Office has approved the patent application for PDS0101, and a patent is expected to be granted after final steps are completed, supporting long-term protection of this lead asset.

Does the PDSB 8-K provide financial or clinical results for PDS0101?

No, the report focuses on the patent Notice of Allowance for PDS0101 and does not include financial metrics or clinical trial results in the provided excerpt.

How did PDSB communicate this patent development to investors?

PDS Biotechnology issued a press release dated January 22, 2026, which is attached as Exhibit 99.1 to the report and incorporated by reference.

Who signed the PDSB Form 8-K related to the PDS0101 patent notice?

The report was signed on behalf of PDS Biotechnology Corporation by Frank Bedu-Addo, Ph.D., the companys President and Chief Executive Officer.